United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698) - dextrose monohydrate 1.5 g in 100 ml - dianeal peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure. dianeal peritoneal dialysis solutions are contraindicated in patients with severe lactic acidosis. dianeal peritoneal dialysis solution is a pharmacologically inactive solution. while there are no adequate and well controlled studies in pregnant women, appropriate administration of dianeal solutions, with appropriate monitoring of hematology, electrolytes, blood chemistry and fluid status is not expected to cause fetal harm. animal reproduction studies have not been conducted with dianeal solutions. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the components of dianeal solutions are excreted in human milk. safety and effectiveness have been established based on published clinic

United States - English - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target

United States - English - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - dextrose monohydrate 50 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for admin

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions, drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. according to the who expert committee on drug dependence, dextromethorphan could produce very slight psychic dependence but no physical dependence.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions, drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. promethazine products are contraindicated for use in pediatric patients less than two years of age. caution should be exercised when administering promethazine products to pediatric patients 2 years of age and older because of the potential for fatal respiratory depression. respiratory depression and apnea, sometimes associated with death, are strongly associated with promethazine products and are n

United States - English - NLM (National Library of Medicine)

proficient rx lp - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions,drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. promethazine products are contraindicated for use in pediatric patients less than two years of age. caution should be exercised when administering promethazine products to pediatric patients 2 years of age and older because of the potential for fatal respiratory depression. respiratory depression and apnea, sometimes associated with death, are strongly associated with promethazine products and are no

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions, drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. according to the who expert committee on drug dependence, dextromethorphan could produce very slight psychic dependence but no physical dependence.

United States - English - NLM (National Library of Medicine)

par pharmaceutical - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions, drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. according to the who expert committee on drug dependence, dextromethorphan could produce very slight psychic dependence but no physical dependence.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions, drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. according to the who expert committee on drug dependence, dextromethorphan could produce very slight psychic dependence but no physical dependence.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - dextromethorphan hydrobromide 15 mg in 5 ml - promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (maoi) (see precautions, drug interactions ). promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. promethazine products are contraindicated for use in pediatric patients less than two years of age. caution should be exercised when administering promethazine products to pediatric patients 2 years of age and older because of the potential for fatal respiratory depression. respiratory depression and apnea, sometimes associated with death, are strongly associated with promethazine products and are n